Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD)

Launched by NEUROMED IRCCS · May 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for Huntington's disease (HD), a condition that causes uncontrolled movements, known as chorea. Researchers want to see if a method called transcranial static magnetic stimulation (tSMS), which is a non-invasive way to stimulate the brain using magnets, can help reduce these involuntary movements when used at home over several sessions.

To participate in this trial, individuals must have a confirmed diagnosis of Huntington's disease and show signs of chorea that can be measured. They should also be able to give their written consent and not have changed their medication for at least eight weeks before the study starts. However, certain people, such as those who are pregnant or have a high risk of suicide, may not be eligible. Participants can expect to receive this brain stimulation treatment in a safe and controlled environment, which could potentially help improve their symptoms. The trial is currently not recruiting participants, but it offers an exciting opportunity for those affected by HD to explore new treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of HD genetically confirmed (number of CAG triplets ≥36)
• • Presence of chorea movements quantified with a score ≥ 10 on the sum of the scores of the subscale of the Unified Huntington's Disease Rating Scale (UHDRS) for the evaluation of maximum chorea for the facial, oro-bucco-lingual, truncal, four limbs districts
• • Ability to provide written informed consent
• • No changes in drug therapy in the 8 weeks prior to the baseline visit
• • No changes in drug therapy for the entire duration of the study
• Exclusion Criteria:
• • Contraindications to exposure to magnetic fields
• • Patients who are pregnant or breastfeeding
• • Presence of significant risk of suicidal behavior
• • Patients who have received an investigational drug in a clinical trial within 30 days of the baseline visit or have planned to use such an investigational drug during the study